Arch Therapeutics Inc (ARTH)

[jsmith123343]

Bottom line...if Arth ends 2017 with the following -
- approval of CE (or close to getting it).
- progress on FDA filings - 501k, IDE etc. with some approvals/progress from FDA
- Most importantly. completion of the internal trials..or close to getting results of it. For internal trials, 40 patients might be low...they should be looking at 100+ based on my research of other hemostatic devices pending FDA. No big deal.

Then we can see stock in the $1.5s...so double of current price. At that point should be news about moving to NASDAQ too.